Texas Heart Takes To The CoreoGraft™

This week Hancock Jaffe Laboratories (HJLI) announced a partnership with the Texas Heart Insitute, a world-renowned leader in cardiovascular disease. This partnership, which is...

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

Tailwinds' Take: this is great news for their second product, the CoreoGraft. Texas Heart is a world class partner and the end market is...

Hancock Jaffe Appoints Three New Independent Directors

Tailwinds' Take: this is a great endorsement of the products and end markets that HJLI is targeting. The background of each new member is...

Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in...

IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Tailwinds' Take: another step towards being the only FDA approved product for CVI, a multi-billion dollar indication. We believe that the likelihood of this...

New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve

Tailwinds' Take: The VenoValve is progressing towards FDA approval. Once approved, the market size is huge. HJLI is significantly undervalued based on this research. IRVINE,...

Hancock Jaffe Laboratories’ VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders...

IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Counting Down To The VenoValve

With a market cap hovering around $25M, Hancock Jaffe Laboratories stock is severely discounting the success of any of its three products that are...

Catching Up With Hancock Jaffe and The VenoValve…

We had the opportunity to speak with Dr. Marc H. Glickman, the Chief Medical Officer at Hancock Jaffe (HJLI). During our conversation, we discussed...

Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study

Tailwinds' Take: one step closer to first-in-man trials. HJLI is moving down three paths with unique products that could each be a company-maker. IRVINE, Calif.,...

Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study

Tailwinds' Take: another positive step towards an approved product. As what would be the only product in a multi-billion market, the VenoValve has the...

Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer

Tailwinds' Take: with 3 product candidates moving down the pipeline, CEO Rob Berman continues to transform the Company in his vision, positioning them for...

Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve

Tailwinds' Take: Hancock Jaffe has the funding to get their 3 lead products in front of the FDA, each of which should be a...

The VenoValve is Hancock Jaffe’s Golden Ticket

When I last wrote about Hancock Jaffe (HJLI), the topic was how the weakness around their IPO created a buying opportunity for forward looking...

Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study

Tailwinds' Take: an important step towards approval as the first valve in the market for treating CVI, a potentially multi-billion dollar market annually. HJLI...

Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriter’s Over Allotment

Tailwinds' Take: The stock has held in despite the shoe not being exercised at all. There is a slew of catalysts coming soon and...

Hancock Jaffe IPO Weakness Is a Buying Opportunity

Sometimes Wall Street gets it wrong. In the epic masterpiece Bonfire of the Vanities, the financial geniuses on Wall Street were referred to as Masters of...

Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering

IRVINE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards...

Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering

IRVINE, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards...